Breakthrough Rhinocerebral Mucormycosis in a Liver Transplant Patient Receiving Caspofungin

Transplantation Proceedings

Volumn 41, Issue 5, 2009, Pages 1972-1975

  Ramos, A ^a   Cuervas Mons, V ^a   Noblejas, A ^a   Banos I ^a   Duran, P ^a   Marcos, R ^a   Sanchez Turrion V ^a   Jimenez M ^a   Arellano, B ^a   Corbacho, C ^a   Sanchez Romero I ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CEFOTAXIME; CIPROFLOXACIN; DACLIZUMAB; FLUCONAZOLE; FRESH FROZEN PLASMA; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PIPERACILLIN PLUS TAZOBACTAM; STEROID; VANCOMYCIN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALBUMIN DIALYSIS; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL INFECTION; CANDIDA ALBICANS; CASE REPORT; CAUSE OF DEATH; DEVICE INFECTION; DISEASE ASSOCIATION; DRUG WITHDRAWAL; ECHOGRAPHY; EPIGASTRIC PAIN; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; FUNGUS CULTURE; FUNGUS ISOLATION; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS; HUMAN; HYPOTHERMIA; HYPOXEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LABORATORY TEST; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MUCORMYCOSIS; MULTIPLE ORGAN FAILURE; NONHUMAN; PLASMA TRANSFUSION; PNEUMONIA; PRIORITY JOURNAL; REPEATED DRUG DOSE; RHIZOPUS; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; ANTIFUNGAL AGENTS; ECHINOCANDINS; FATAL OUTCOME; FEMALE; FLUCONAZOLE; HEPATITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MUCORMYCOSIS; RHIZOPUS;

EID: 67249090524     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.01.077     Document Type: Article

References (37)

1. Ribes J.A., Vanover-Sams C.L., and Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 13 (2000) 236
2. Petrovic J., Ngai A., Bradshaw S., et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc 39 (2007) 3117
3. Vetrone G., Grazi G.L., Ercolani G., et al. Successful treatment of rhinomaxillary form of mucormycosis infection after liver transplantation: a case report. Transplantl Proc 38 (2006) 1445
4. Silveira F.P., and Husain S. Fungal infections in solid organ transplantation. Med Mycol 45 (2007) 305
5. Petrikkos G., and Skiada A. Recent advances in antifungal chemotherapy. Int J Antimicrob Agents 30 (2007) 108
6. Singh N., Gayowski T., and Yu V.L. Invasive gastrointestinal zygomycosis in a liver transplant recipient: case report and review of zygomycosis in solid-organ transplant recipients. Clin Infect Dis 20 (1995) 617
7. Uçkay I., Chalandon Y., Sartoretti P., et al. Invasive zygomycosis in transplant recipients. Clin Transplant 21 (2007) 577
8. Almyroudis N.G., Sutton D.A., Linden P., et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 6 (2006) 2365
9. Jimenez C., Lumbreras C., Aguado J.M., et al. Successful treatment of mucor infection after liver or pancreas-kidney transplantation. Transplantation 73 (2002) 476
10. Chen Y.S., Chen C.L., Liu P.P., et al. Successful treatment of invasive mucormycosis following liver transplantation. Transplant Proc 28 (1996) 1708
11. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41 (2005) 634
12. Torres-Narbona M., Guinea J., Martínez-Alarcón J., et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob Agents Chemother 51 (2007) 1126
13. Girmenia C., Moleti M.L., Micozzi A., et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 43 (2005) 5395
14. Safdar A., O'Brien S., and Kouri I.F. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant 34 (2004) 467
15. Vazquez L., Mateos J.J., Sanz-Rodriguez C., et al. Successful treatment of rhinocerebral zygomycosis with a combination of caspofungin and liposomal amphotericin B. Haematologica 90 (2005) e109
16. Lumbreras C., Cuervas-Mons V., Jara P., et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 174 (1996) 583
17. Page R.L., Schwiesow J., and Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy 27 (2007) 290
18. Ferguson B.J. Mucormycosis of the nose and paranasal sinuses. Otolaryngol Clin North Am 33 (2000) 349
19. Blumberg E.A., and Reboli A.C. Failure of systemic empirical treatment with amphotericin B to prevent candidemia in neutropenic patients with cancer. Clin Infect Dis 22 (1996) 462
20. Nguyen M.H., Peacock Jr. J.E., Morris A.J., et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 100 (1996) 617
21. Krcmery V., Jesenska Z., Spanik S., et al. Fungaemia due to Fusarium spp. in cancer patients. J Hosp Infect 36 (1997) 223
22. Krcmery Jr. V., Mateicka F., Grausova S., et al. Invasive infections due to Clavispora Iusitaniae. FEMS Immunol Med Microbiol 23 (1999) 75
23. Safdar A., van Rhee F., Henslee-Downey J.P., et al. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome. Bone Marrow Transplant 28 (2001) 873
24. Vigouroux S., Morin O., Moreau P., et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 40 (2005) e35
25. Blin N., Morineau N., Gaillard F., et al. Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 45 (2004) 2161
26. Rieger C., Geiger S., Herold T., et al. Breakthrough infection of Trichosporon asahii during posaconazole treatment in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 26 (2007) 843
27. Tong S.Y., Peleg A.Y., Yoong J., et al. Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transpl Infect Dis 9 (2007) 241
28. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191 (2005) 1350
29. Walsh T.J., Tepplet H., Donowitz G.R., et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351 (2004) 1391
30. Webb M., Dowdy L., Bundschu C., et al. Cerebral mucormycosis after liver transplantation: a case report. Clin Transplant 12 (1998) 596
31. Alexander B.D. Prophylaxis of invasive mycoses in solid organ ransplantation. Curr Opin Infect Dis 15 (2002) 583
32. Cheung C., Guo Y., Gialanella P., et al. Development of candidemia on caspofungin therapy: a case report. Infection 34 (2006) 345
33. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole profilaxis in patients singh neutropenia. N Engl J Med 356 (2007) 348
34. Reed A., Herndon J.B., Ersoz N., et al. Effect of prophylaxis on fungal infection and costs for high-risk liver transplant recipients. Liver Transpl 13 (2007) 1743
35. Shah T., Lai W.K., Gow P., et al. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation. Transpl Infect Dis 7 (2005) 126
36. van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42 (2006) e61
37. Greenberg R.N., Mullane K., van Burik J.A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50 (2006) 126